Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.37 USD | -0.88% | -7.13% | +31.46% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.46% | 262M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M